

(12) United States Patent

Asaki et al.

US 7,205,302 B2 (10) Patent No.:

(45) Date of Patent: Apr. 17, 2007

(54) HETEROCYCLIC COMPOUND **DERIVATIVES AND MEDICINES**

(75) Inventors: **Tetsuo Asaki**, Kyoto (JP); **Taisuke** Hamamoto, Osaka (JP); Keiichi

Kuwano, Osaka (JP)

Assignee: Nippon Shinyaku Co., Ltd., Kyoto

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 344 days.

10/476,196 (21) Appl. No.:

(22) PCT Filed: Apr. 25, 2002

(86) PCT No.: PCT/JP02/04118

§ 371 (c)(1),

Oct. 23, 2003 (2), (4) Date:

(87) PCT Pub. No.: WO02/088084

PCT Pub. Date: Nov. 7, 2002

(65)**Prior Publication Data**

US 2004/0102436 A1 May 27, 2004

(30)Foreign Application Priority Data

Apr. 26, 2001 (JP) 2001-129765

- (51) Int. Cl. C97D 241/18 (2006.01)(2006.01)C07D 241/20 A61K 31/4966 (2006.01)A61P 7/02 (2006.01)A61P 9/08 (2006.01)A61P 9/10 (2006.01)A61P 9/12 (2006.01)C07D 253/065 (2006.01)C07D 239/42 (2006.01)C07D 213/74 (2006.01)A61K 31/53 (2006.01)A61K 31/505 (2006.01)A61K 31/4488 (2006.01)
- (52) **U.S. Cl.** **514/252.1**; 544/336; 544/408; 544/180; 544/216; 544/297; 544/298; 514/241; 514/245; 514/269; 514/272; 514/345; 514/352; 546/300; 546/301
- 544/336, (58) Field of Classification Search 544/408; 514/252.1 See application file for complete search history.

(56)References Cited

FOREIGN PATENT DOCUMENTS

0 088 593 A2 EP 9/1983

GB	1 604 084	12/1981
JP	7-33752 A1	2/1992
JP	5-208961 A1	8/1993
JP	5-508845 A1	12/1993
WO	WO-92/01675 A2	2/1992
WO	WO-92/02513 A1	2/1992

OTHER PUBLICATIONS

Meanwell, Nicholas A. et al., Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety, J. Med. Chem., 1992, vol. 35, No. 19, pp. 3498 to 3512; particularly, compound Nos. 13aw, 13ax, 13aaa on table II.

Konno, Shoetsu et al., Studies on as-triazine derivatives. XIX. Synthesis of 2, 3-diarylpyrazine and 2, 3-diarypyridine derivatives as blood platelet aggregation inhibitors. Yakugaku Zasshi, 1993, vol. 113, No. 1, pp. 40 to 52; particularly, tables III, IV.

Bhalla, M. et al., Synthesis and pharmacological evaluation of 1, 2, 4-triazine and its congeners, Boll. Chim. Farm., 1995, vol. 134, No. 1, pp. 9 to 15; compounds on formulas IV, V of Fig. 1.

Primary Examiner—Venkataraman Balasubramanian (74) Attorney, Agent, or Firm—Darby & Darby

(57)ABSTRACT

The present invention provides a compound which is useful as a PGI₂ receptor agonist, and a pharmaceutical composi-

The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]:

$$\begin{array}{c} R^{1} \\ Y \\ Z \\ N \end{array}$$

$$\begin{array}{c} X \\ A - D - E - G - C - Q \end{array}$$

$$(1)$$

(R¹ and R² are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR5, O, S, or ethylene, R5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH₂, R³ and R⁴ are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.

15 Claims, No Drawings